Rare diseases
Investigational molecules
Locations
Study on Long-Term Safety of Ianalumab for Patients with Systemic Lupus Erythematosus
BulgariaDoxycycline post‑exposure prophylaxis for sexually transmitted infections in MSM and transgender women on antiretroviral drug combination
SpainSwitching to Lenacapavir, Teropavimab, and Zinlirvimab in Virologically Suppressed Adults with HIV-1: A Phase 3 Randomized Study
FranceSafety and Tolerability of Tenofovir Alafenamide Dose Escalation in Healthy Adults for Epstein‑Barr Virus Infection
NorwayA study of islatravir and ulonivirine for adults with HIV who have not received previous treatment
FranceA study testing VH4524184 with emtricitabine and tenofovir alafenamide compared to dolutegravir and lamivudine in adults with HIV-1 who have not received treatment before
BelgiumStudy on the Effects and Safety of Ianalumab in Adults with Lupus Nephritis Who Completed Previous Treatment
CzechiaStudy on the Effectiveness and Safety of Ianalumab for Patients with Diffuse Cutaneous Systemic Sclerosis
AustriaStudy on the Effects and Safety of Bulevirtide, Peginterferon Alfa-2a, and Entecavir in Patients with Chronic Hepatitis D
SwedenPhase III trial evaluating ianalumab with background drug combination in patients with Sjögren's disease
CzechiaStudy of Emtricitabine, Tenofovir Alafenamide and Bictegravir in Adults with HIV Undergoing Analytical Treatment Interruption
SpainStudy of Tenofovir Alafenamide as Add-on Treatment to Anti-CD20 Therapy in Multiple Sclerosis Patients to Reduce Neuronal Damage
NorwayTell us about your condition – we search every trial in Europe and connect you with the right site.
